The most commonly reported adverse events associated with the use of Gelnique® included dry mouth (6.9%), urinary tract infection (6.9%), and application site reactions (5.4%). Gelnique® is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, or known hypersensitivity to Gelnique®, including skin hypersensitivity and in patients who are at risk for these conditions. Gelnique® should be used with caution in patients with hepatic or renal impairment, clinically significant bladder outflow obstruction, myasthenia gravis, and gastrointestinal obstructive disorders. Gelnique® should also be used with caution in patients with conditions such as ulcerative colitis, intestinal atony, gastroesophageal reflux and those concurrently taking drugs that can cause or exacerbate esophagitis. Patients who develop skin hypersensitivity to Gelnique® should discontinue drug treatment. Angioedema requiring hospitalization and emergency medical treatment has occurred with the first or subsequent doses of oxybutynin pills. If angioedema occurs, Gelnique® should be discontinued and appropriate therapy promptly provided. Transference of oxybutynin to another person can occur when vigorous skin-to-skin contact is made with the application site. Patients should be instructed to avoid open fire or smoking until the gel has dried.